浙江衆成(002522.SZ):控股子公司的氫化苯乙烯/異戊二烯嵌段共聚物(SEPS)系列產品所形成的營收佔比較小
格隆匯2月26日丨浙江衆成(002522.SZ)公佈,公司注意到近期市場上關於AI+成人相關熱點概念的關注度較高。公司控股子公司浙江衆立合成材料科技股份有限公司的主營業務爲熱塑性彈性體的研發、生產和銷售,其所開發的氫化苯乙烯/異戊二烯嵌段共聚物(SEPS)系列產品可用於實體娃娃等成人用品領域,該系列產品已實現量產並形成多年穩定的供應銷售,但目前其所形成的營業收入在公司營業總收入中所佔的比例較小。公司主營業務保持平穩,未出現大幅度波動。敬請廣大投資者理性投資,注意風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.